Published in Mol Pharmacol on July 01, 2003
N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene (2006) 2.03
N-acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice. J Pharmacol Exp Ther (2006) 0.97
Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements. Drug Metab Dispos (2007) 0.96
Loss of function polymorphisms in NAT1 protect against spina bifida. Hum Genet (2006) 0.94
RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS One (2011) 0.90
Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene. J Clin Invest (2015) 0.90
Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br J Pharmacol (2014) 0.87
Expression of folate pathway genes in the cartilage of Hoxd4 and Hoxc8 transgenic mice. Birth Defects Res A Clin Mol Teratol (2006) 0.87
Systemic functional expression of N-acetyltransferase polymorphism in the F344 Nat2 congenic rat. Drug Metab Dispos (2008) 0.85
Mouse arylamine N-acetyltransferase 2 (Nat2) expression during embryogenesis: a potential marker for the developing neuroendocrine system. Biomarkers (2008) 0.85
Tissue expression and genomic sequences of rat N-acetyltransferases rNat1, rNat2, rNat3, and Functional characterization of a novel rNat3*2 genetic variant. Toxicol Sci (2007) 0.84
Quantitative tissue and gene-specific differences and developmental changes in Nat1, Nat2, and Nat3 mRNA expression in the rat. Drug Metab Dispos (2008) 0.84
Reduced 4-aminobiphenyl-induced liver tumorigenicity but not DNA damage in arylamine N-acetyltransferase null mice. Cancer Lett (2011) 0.81
An acetyltransferase conferring tolerance to toxic aromatic amine chemicals: molecular and functional studies. J Biol Chem (2009) 0.79
Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese. Drug Metab Dispos (2011) 0.79
A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat (2016) 0.77
Potential of N-acetylated-para-aminosalicylic acid to accelerate manganese enhancement decline for long-term MEMRI in rodent brain. J Neurosci Methods (2015) 0.77
Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines. Cancer Med (2015) 0.76
Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding. BMC Pharmacol Toxicol (2014) 0.76
N-acetyltransferase 2 activity and folate levels. Life Sci (2009) 0.76
N-hydroxylation of 4-aminobiphenyl by CYP2E1 produces oxidative stress in a mouse model of chemically induced liver cancer. Toxicol Sci (2015) 0.75
Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis. Inflamm Bowel Dis (2016) 0.75
Deficiency of N-Acetyltransferase Increases the Interactions of Isoniazid with Endobiotics in mouse Liver. Biochem Pharmacol (2017) 0.75
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet (2006) 3.72
Behavior-change action plans in primary care: a feasibility study of clinicians. J Am Board Fam Med (2006) 2.51
Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res (2010) 2.06
Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician (2007) 1.83
Using action plans to help primary care patients adopt healthy behaviors: a descriptive study. J Am Board Fam Med (2006) 1.64
Limited association of the 2988g > a single nucleotide polymorphism with CYP2D641 in black subjects. Clin Pharmacol Ther (2005) 1.49
Evaluation of the Centers for Disease Control and Prevention's concussion initiative for high school coaches: "Heads Up: Concussion in High School Sports". J Sch Health (2010) 1.35
Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther (2005) 1.35
Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology (2008) 1.26
Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes. Development (2013) 1.23
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther (2003) 1.22
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther (2004) 1.20
Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet (2013) 1.16
Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr (2004) 1.10
Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit. J Med Chem (2008) 1.08
Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J Biol Chem (2007) 1.07
Detection of modifier loci influencing the lung phenotype of cystic fibrosis knockout mice. Mamm Genome (2002) 1.06
Dissociated phenotypes in presenilin transgenic mice define functionally distinct gamma-secretases. Proc Natl Acad Sci U S A (2005) 1.05
In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4α expression. Drug Metab Dispos (2012) 1.00
Establishment and results of a magnetic resonance quality assurance program for the pediatric brain tumor consortium. Acad Radiol (2008) 0.99
Kinetic characterization and identification of a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 using a time-resolved fluorescence resonance energy transfer-based assay technology. Anal Biochem (2008) 0.99
Diacylglycerol kinases as sources of phosphatidic acid. Biochim Biophys Acta (2009) 0.99
Tracking Trichophyton tonsurans through a large urban child care center: defining infection prevalence and transmission patterns by molecular strain typing. Pediatrics (2006) 0.98
Men can cook! Development, implementation, and evaluation of a senior men's cooking group. J Nutr Elder (2004) 0.97
Regulation of neurite outgrowth in N1E-115 cells through PDZ-mediated recruitment of diacylglycerol kinase zeta. Mol Cell Biol (2005) 0.95
Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand. N Z Med J (2004) 0.93
Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol (2008) 0.93
Health literacy programs for older adults: a systematic literature review. Health Educ Res (2012) 0.93
The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. Neurobiol Aging (2011) 0.93
Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother (2006) 0.92
Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology (2006) 0.92
Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med (2008) 0.92
Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol (2005) 0.91
Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenet Genomics (2008) 0.91
Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol (2010) 0.91
Omeprazole disposition in children following single-dose administration. J Clin Pharmacol (2003) 0.90
Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet (2010) 0.90
Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype. J Clin Pharmacol (2008) 0.89
Systematic review of the literature on postpartum care: methodology and literature search results. Birth (2004) 0.88
Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos (2010) 0.88
3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase. J Med Chem (2008) 0.88
Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet (2013) 0.87
Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenet Genomics (2013) 0.86
CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy (2002) 0.86
Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants. Pharmacogenomics (2013) 0.86
Regulation of microRNA expression by rifampin in human hepatocytes. Drug Metab Dispos (2013) 0.85
High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays. Assay Drug Dev Technol (2006) 0.85
The action plan project: discussing behavior change in the primary care visit. Ann Fam Med (2005) 0.85
Nurse reports of adverse events during sedation procedures at a pediatric hospital. J Perianesth Nurs (2009) 0.84
Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. J Clin Pharmacol (2008) 0.84
Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis (2009) 0.84
Exploring older adults' health information seeking behaviors. J Nutr Educ Behav (2011) 0.84
Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Child (2011) 0.83
Loss of nicastrin elicits an apoptotic phenotype in mouse embryos. Brain Res (2006) 0.83
5-methyl-tetrahydrofolate and the S-adenosylmethionine cycle in C57BL/6J mouse tissues: gender differences and effects of arylamine N-acetyltransferase-1 deletion. PLoS One (2013) 0.83
Systematic review of the literature on postpartum care: selected contraception methods, postpartum Papanicolaou test, and rubella immunization. Birth (2004) 0.83
Systematic literature review of randomized control trials assessing the effectiveness of nutrition interventions in community-dwelling older adults. J Nutr Educ Behav (2011) 0.83
Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab Dispos (2002) 0.82
Development and implementation of a high-throughput AlphaLISA assay for identifying inhibitors of EZH2 methyltransferase. Assay Drug Dev Technol (2013) 0.82
Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population. Pediatr Nephrol (2014) 0.81
Liver-selective expression of human arylamine N-acetyltransferase NAT2 in transgenic mice. Drug Metab Dispos (2011) 0.81
Differential display analysis of presenilin 1-deficient mouse brains. Brain Res Mol Brain Res (2002) 0.81
Reduced 4-aminobiphenyl-induced liver tumorigenicity but not DNA damage in arylamine N-acetyltransferase null mice. Cancer Lett (2011) 0.81
Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjects. Clin Pharmacol Ther (2003) 0.81
Diacylglycerol kinase ζ regulates RhoA activation via a kinase-independent scaffolding mechanism. Mol Biol Cell (2012) 0.81
Genetic transmission of cytochrome P450 2D6 (CYP2D6) ultrarapid metabolism: implications for breastfeeding women taking codeine. Curr Drug Saf (2011) 0.80
Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis. Clin Pharmacol Ther (2004) 0.80
Defining risk factors for red man syndrome in children and adults. Pediatr Infect Dis J (2012) 0.80
Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin Pharmacol Ther (2002) 0.80
Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur J Clin Pharmacol (2005) 0.80
Discovery of amido-benzisoxazoles as potent c-Kit inhibitors. Bioorg Med Chem Lett (2008) 0.80
Small molecules with potent osteogenic-inducing activity in osteoblast cells. Bioorg Med Chem Lett (2009) 0.79
Online marketing of food and beverages to children: a content analysis. Can J Diet Pract Res (2010) 0.79
CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genes. Pharmacogenet Genomics (2012) 0.79
Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping. J Clin Pharmacol (2004) 0.78
CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects. Pharmacogenomics (2014) 0.78
Comparison of 2 cell-based phosphoprotein assays to support screening and development of an ALK inhibitor. J Biomol Screen (2011) 0.77
High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6. Pharmacogenomics (2013) 0.77
Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers. J Clin Pharmacol (2004) 0.77
Multilocus genotyping identifies infections by multiple strains of Trichophyton tonsurans. J Clin Microbiol (2007) 0.77
Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement. Clin Ther (2008) 0.77
Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics (2014) 0.77
Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase. Bioorg Med Chem Lett (2005) 0.77
Genetic variants of the drug-metabolizing enzyme CYP2D6 in Puerto Rican psychiatry patients: a preliminary report and potential implications for breast cancer patients. P R Health Sci J (2010) 0.77
Influence of arylamine N-acetyltransferase, sex, and age on 4-aminobiphenyl-induced in vivo mutant frequencies and spectra in mouse liver. Environ Mol Mutagen (2012) 0.77
Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 Test no-call in the clinical setting. Clin Chem Lab Med (2014) 0.76
Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. Eur J Clin Pharmacol (2006) 0.76
Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors. J Med Chem (2016) 0.76
Food workshops, nutrition education, and older adults: a process evaluation. J Nutr Elder (2005) 0.76
Paradoxical attenuation of autoimmune hepatitis by oral isoniazid in wild-type and N-acetyltransferase-deficient mice. Drug Metab Dispos (2014) 0.76
Comments on Hoskins et al. [(2005) drug metab dispos 33:1564-1565]. Drug Metab Dispos (2006) 0.75
Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder. Medicine (Baltimore) (2016) 0.75
Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities. J Med Chem (2017) 0.75
Correction to "Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement". ACS Med Chem Lett (2017) 0.75
Promoting eHealth literacy in older adults: key informant perspectives. Can J Diet Pract Res (2013) 0.75
Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity. J Med Chem (2017) 0.75
A laboratory study on the kinetics of the formation of oil-suspended particulate matter aggregates using the NIST-1941b sediment. Mar Pollut Bull (2010) 0.75
Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors. J Med Chem (2011) 0.75